Get startedLog in
    Picture of Swedish Orphan Biovitrum AB (publ) logo

    SOBI — Swedish Orphan Biovitrum AB (publ) News Story

    0.000.00%
    se flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    US FDA declines to approve Sobi's therapy for uncontrolled gout

    Picture of Swedish Orphan Biovitrum AB (publ) logoSwedish Orphan Biovitrum AB (publ)
    26/06/2026 20:19
    US FDA declines to approve Sobi's therapy for uncontrolled gout 
    June 26 (Reuters) - The U.S. Food and Drug Administration declined to approve Swedish drugmaker Sobi's SOBIV.ST therapy to treat uncontrolled gout, a common form of inflammatory arthritis, the company said on Friday.


     (Reporting by Sneha S K and Puyaan Singh in Bengaluru; Editing by Leroy Leo and Sahal Muhammed)
     ((Sneha.SK@thomsonreuters.com;))

    Recent news on Swedish Orphan Biovitrum AB (publ)

    See all news